Literature DB >> 21993830

Neuro-oncological diagnosis in patients without histological confirmation.

P Gaviani1, A Silvani, E Lamperti, A Botturi, G Simonetti, D Ferrari, A Salmaggi.   

Abstract

The impossibility to conduct a histological diagnosis could be due to different reasons: (1) patient's refusal to undergo surgery/biopsy. (2) Technical difficulties: despite the advance in surgical procedures, the removal of lesions that are located either in critical or in deep areas represents a considerable risk for patients. (3) Quality/quantity of the sample. In rare cases even when the surgical sample is achieved it could be impossible to reach a histological confirmation, for example due to the small amount of tissue obtained. The lack of histology leads to suboptimal therapy, incorrect prognosis, and misinterpretation of clinical trials and furthermore undermines the possibility to perform most radiation and chemotherapy protocols. In this setting the morphological data obtained with conventional MR imaging may be integrated with the metabolic, structural and perfusional information provided by new MR and metabolic techniques (spectroscopy, SPECT, PET in particular).

Entities:  

Mesh:

Year:  2011        PMID: 21993830     DOI: 10.1007/s10072-011-0790-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  7 in total

Review 1.  Diffuse brainstem tumors: when is a biopsy necessary?

Authors:  A L Albright
Journal:  Pediatr Neurosurg       Date:  1996       Impact factor: 1.162

2.  Stereotactic biopsy for brain tumors: is it always necessary?

Authors:  J Vaquero; R Martínez; M Manrique
Journal:  Surg Neurol       Date:  2000-05

3.  Limitations of stereotactic biopsy in the initial management of gliomas.

Authors:  R J Jackson; G N Fuller; D Abi-Said; F F Lang; Z L Gokaslan; W M Shi; D M Wildrick; R Sawaya
Journal:  Neuro Oncol       Date:  2001-07       Impact factor: 12.300

4.  Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients.

Authors:  Wilhelm Küker; Thomas Nägele; Agnieska Korfel; Stefan Heckl; Eckhard Thiel; Michael Bamberg; Michael Weller; Ulrich Herrlinger
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

5.  Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens.

Authors:  C Dowling; A W Bollen; S M Noworolski; M W McDermott; N M Barbaro; M R Day; R G Henry; S M Chang; W P Dillon; S J Nelson; D B Vigneron
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

Review 6.  The role of stereotactic biopsy in the management of gliomas.

Authors:  D Kondziolka; L D Lunsford
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

7.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.

Authors:  Meng Law; Stanley Yang; Hao Wang; James S Babb; Glyn Johnson; Soonmee Cha; Edmond A Knopp; David Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

  7 in total
  1 in total

1.  MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: nanoclinic in the brain.

Authors:  Rameshwar Patil; Alexander V Ljubimov; Pallavi R Gangalum; Hui Ding; Jose Portilla-Arias; Shawn Wagner; Satoshi Inoue; Bindu Konda; Arthur Rekechenetskiy; Alexandra Chesnokova; Janet L Markman; Vladimir A Ljubimov; Debiao Li; Ravi S Prasad; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  ACS Nano       Date:  2015-05-06       Impact factor: 15.881

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.